A Pilot Study of Dual Treatment With Recombinant Tissue Plasminogen Activator and Uric Acid in Acute Ischemic Stroke | Zendy

Sergio Amaro | Zendy; Dolors Soy | Zendy; Vı́ctor Obach | Zendy; Álvaro Cervera | Zendy; Anna M. Planas | Zendy; Ángel Chamorro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Pilot Study of Dual Treatment With Recombinant Tissue Plasminogen Activator and Uric Acid in Acute Ischemic Stroke

Author(s) -

Sergio Amaro,

Dolors Soy,

Vı́ctor Obach,

Álvaro Cervera,

Anna M. Planas,

Ángel Chamorro

Publication year - 2007

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.106.480699

Subject(s) - medicine , stroke (engine) , malondialdehyde , lipid peroxidation , uric acid , tissue plasminogen activator , gastroenterology , lesion , surgery , anesthesia , oxidative stress , mechanical engineering , engineering

Uric acid (UA) increases the neuroprotective effects of recombinant tissue plasminogen activator (rt-PA) in experimental ischemia. In patients with stroke, increased UA levels have been linked to better stroke recovery, but the clinical safety of dual administration of UA and rt-PA is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research